The impairment of growth hormone (GH)/insulin growth factor-1(IGF-1) plays a crucial role in chronic heart failure (CHF). Several studies have shown that patients affected by this condition display a more aggressive disease, with impaired functional capacity and poor outcomes. Interestingly, GH replacement therapy represents a possible future therapeutic option in CHF. In this review, the authors focus on the assessment of the main abnormalities in GH/IGF-1 axis in CHF, the underlying molecular background, and their impact on disease progression and outcomes.
Growth Hormone as Biomarker in Heart Failure / Marra, Alberto M.; Bobbio, Emanuele; D'Assante, Roberta; Salzano, Andrea; Arcopinto, Michele; Bossone, Eduardo; Cittadini, Antonio. - In: HEART FAILURE CLINICS. - ISSN 1551-7136. - 14:1(2018), pp. 65-74. [10.1016/j.hfc.2017.08.008]
Growth Hormone as Biomarker in Heart Failure
Marra, Alberto M.;D'Assante, Roberta;Salzano, Andrea;Arcopinto, Michele;Bossone, Eduardo;Cittadini, Antonio
2018
Abstract
The impairment of growth hormone (GH)/insulin growth factor-1(IGF-1) plays a crucial role in chronic heart failure (CHF). Several studies have shown that patients affected by this condition display a more aggressive disease, with impaired functional capacity and poor outcomes. Interestingly, GH replacement therapy represents a possible future therapeutic option in CHF. In this review, the authors focus on the assessment of the main abnormalities in GH/IGF-1 axis in CHF, the underlying molecular background, and their impact on disease progression and outcomes.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
